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Clinical and cost-effectiveness of a New
psychosocial intervention to support
Independence in Dementia (NIDUS-family)
for family carers and people living with
dementia in their own homes: a
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Iain Lang10, Gill Livingston2, Briony Dow11, Helen Kales12, Jill Manthorpe13, Kate Walters6, Juanita Hoe14,
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Abstract
Background: Most people living with dementia want to remain living in their own homes and are supported to
do so by family carers. No interventions have consistently demonstrated improvements to people with dementia’s
life quality, functioning, or other indices of living as well as possible with dementia. We have co-produced, with
health and social care professionals and family carers of people with dementia, a new intervention (NIDUS-family).
To our knowledge, NIDUS-family is the first manualised intervention that can be tailored to personal goals of
people living with dementia and their families and is delivered by facilitators without clinical training. The
intervention utilizes components of behavioural management, carer support, psychoeducation, communication and
coping skills training, enablement, and environmental adaptations, with modules selected to address dyads’
selected goals. We will evaluate the effect of NIDUS-family and usual care on goal attainment, as measured by Goal
Attainment Scaling (GAS) rated by family carers, compared to usual care alone at 12-month follow-up. We will also
determine whether NIDUS-family and usual care is more cost-effective than usual care alone over 12 months.
Methods: A randomised, two-arm, single-masked, multi-site clinical trial involving 297 people living with dementia-
family carer dyads. Dyads will be randomised 2:1 to receive the NIDUS-family intervention with usual care (n = 199)
or usual care alone (n = 98). The intervention group will be offered, over 1 year, via 6–8 video call or telephone
sessions (or face to face if COVID-19 restrictions allow in the recruitment period) in the initial 6 months, followed by
telephone follow-ups every 1–2 months to support implementation, with a trained facilitator.
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Discussion: Increasing the time lived at home by people living with dementia is likely to benefit lives now and in
the future. Our intervention, which we adapted to include remote delivery prior to trial commencement due to the
COVID-19 pandemic, aims to address barriers to living as well and as independently as possible that distress people
living with dementia, exacerbate family carer(s) stress, negatively affect relationships, lead to safety risks, and
frequently precipitate avoidable moves to a care home.
Trial registration: International Standard Randomised Controlled Trials Number ISRCTN11425138. Registered on 7
October 2019
Keywords: Dementia, Family carer, Psychosocial intervention, Independence
Administrative information
Note: the numbers in curly brackets in this protocol
refer to SPIRIT checklist item numbers. The order of




Title {1} Clinical and cost-effectiveness of a
New psychosocial intervention to
support Independence in Dementia
(NIDUS) for family carers and people
living with dementia in their own
homes: A randomised controlled
trial
Trial registration {2a and 2b}. International Standard Randomised
Controlled Trials Number: ISRC
TN11425138 https://doi.org/10.1186/
ISRCTN11425138
Protocol version {3} Protocol Version 3 (06/04/2020)
Funding {4} This work is supported by Alzheimer’s
Society (UK) and is being carried out
within the University College London
(UCL) Alzheimer’s Society Centre of
Excellence for Independence at home,
NIDUS (New Interventions in Dementia
Study) programme (Alzheimer’s Society
Centre of Excellence grant (AS-PR2-16-
002).
Author details {5a} Department of Behavioural Science and
Health, University College London,
London, UK
Alexandra Burton; a.burton@ucl.ac.uk
Division of Psychiatry, University





uk Gill Livingston g.livingston@ucl.ac.uk
Vasiliki Orgeta v.orgeta@ucl.ac.uk
Department of Statistical Science,
University College London, London, UK
Julie Barber j.barber@ucl.ac.uk
Research Department of Primary Care
and Population Health, University
College London, London, UK
Rachael Hunter r.hunter@ucl.ac.uk Kate
Walters k.walters@ucl.ac.uk




Title {1} Clinical and cost-effectiveness of a
New psychosocial intervention to
support Independence in Dementia
(NIDUS) for family carers and people
living with dementia in their own
homes: A randomised controlled
trial
nhs.uk Claudia Cooper
The Centre for Applied Dementia
Studies, University of Bradford, Bradford,
UK
Kathryn Lord k.lord1@ucl.ac.uk
Faculty of Science and Engineering,
Anglia Ruskin University, Cambridge, UK
Laurie Butler laurie.butler@anglia.ac.uk
Division of Geriatric Medicine,
Dalhousie University, Halifax, Canada
Kenneth Rockwood
Kenneth.Rockwood@Dal.Ca





College of Medicine and Health,
University of Exeter, Exeter, UK
Iain Lang i.lang@exeter.ac.uk
National Ageing Research Institute,
Royal Melbourne Hospital, Victoria,
Australia
Briony Dow B.Dow@nari.edu.au
Department of Psychiatry and
Behavioral Sciences, UC Davis Health,
University of California, California, USA
Helen Kales hckales@ucdavis.edu
NIHR Policy Research Unit in Health and
Social Care Workforce, King’s College
London, London, UK
Jill Manthorpe jill.manthorpe@kcl.ac.uk
Division of Nursing, School of Health
Sciences, City University of London,
London, UK
Juanita Hoe Juanita.Hoe@city.ac.uk
Department of Psychiatry and
Behavioral Sciences, Johns Hopkins
University, Baltimore, Maryland, USA
Quincy Samus qmiles@jhmi.edu
Name and contact
information for the trial
sponsor {5b}




Role of sponsor {5c} Neither the study sponsor (UCL Joint
Research Office), nor the funder
Burton et al. Trials          (2021) 22:865 Page 2 of 14
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Title {1} Clinical and cost-effectiveness of a
New psychosocial intervention to
support Independence in Dementia
(NIDUS) for family carers and people
living with dementia in their own
homes: A randomised controlled
trial
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Introduction
Background and rationale {6a}
Most people with dementia want to remain living in
their own homes and are supported to do so by family
carers. In the UK, 61% of people with dementia live in
the community [1]. Unfortunately, care at home often
breaks down, necessitating a move to a care home,
which can be sudden. Challenging or distressing
behaviours leading to family carer stress, challenging
relationships with home care services, poor self-care,
and home safety risks are common reasons for this [2].
NHS England’s Well Pathway for Dementia and other
national initiatives stress the importance of promoting
independence for people living with dementia [3]. Living
well with dementia has been conceptualised as living
with quality of life, choice, autonomy, dignity, and as
independently as possible. To our knowledge, only two
interventions have demonstrated efficacy in enabling
people with dementia to remain in their own homes for
longer, to date. Both were delivered in the USA, by
clinically trained staff. They were individually tailored
and goal focussed [4, 5].
In stream one of the NIDUS study, we carried out
qualitative interviews [6, 7] and worked with our public
and patient involvement (PPI) co-production group and
practitioners, to develop the theoretical model underpin-
ning our intervention [8] to support people with demen-
tia to attain goals they and their family carers considered
critical to living as well as possible at home. The inter-
vention is fully manualised and modular, so it can be tai-
lored to the needs of each dyad. Modules draw on
behavioural management techniques, enablement strat-
egies, communication, carer support, and psychoeduca-
tion strategies, with material selected from existing
interventions [9–12] and newly developed by the copro-
duction group. We tested the feasibility of the interven-
tion with 14 people living with dementia/family carer
dyads. We found it to be acceptable to participants, and
we used these findings to modify the training and inter-
vention booklets in preparation for the full trial, based
on feedback from participants receiving the intervention
and the researchers delivering it [13].
Our NIDUS-family intervention is delivered to people
with dementia and family carers by NIDUS facilitators
(graduate psychologists/social researchers with relevant
experience but without formal clinical training) with
supervision, training, and clinical oversight, so it can be
widely implemented and give value if effective.
We originally planned to deliver the NIDUS-family
intervention face-to-face to people in their homes; how-
ever, just before the trial started, lockdown restrictions
due to the COVID-19 pandemic were imposed in the
UK. Following discussion with our PPI members and
project management team, we adapted delivery to online
video or telephone sessions, so participants could con-
tinue to receive it until it is deemed safe for researchers
to meet with participants face-to-face. We also adapted
our intervention content, specifically to signpost to re-
mote rather than face-to-face services, to acknowledge
the restricted options for outdoor activity and the
stresses of living through the pandemic lockdown. Most
psychological interventions (NHS and research) for
people living with dementia are being delivered remotely
at the time of writing due to the needs for social distan-
cing during the pandemic. This has illustrated the possi-
bilities of remote delivery as well as challenges.
Interventions can be potentially delivered in people’s
homes very cost-effectively through video calling or over
the telephone, and catchment areas can be widened. Not
everyone has access to video calling, however, and en-
gaging dyads over telephone alone may be particularly
challenging.
Eight-five percent of people asked by the Alzheimer’s
Society said they would want to stay at home for as long
as possible if diagnosed with dementia [14]. The purpose
of our intervention, to increase the time lived at home,
and life quality of people living with dementia by
supporting them and their family carers, is all the more
pertinent in the current climate, with provision of
support services diminished by the COVID-19 restric-
tions [15]. We have selected Goal Attainment Scaling
(GAS) as our primary outcome, asking dyads to set
goals that reflected what they considered most im-
portant in enabling them to live as well and as inde-
pendently as possible at home. GAS can detect
individualised, clinically meaningful outcomes [16],
through measuring the extent to which individual pa-
tients or their families meet goals that they set. It has
been used across many types of interventions and
several conditions with heterogeneous outcomes, in-
cluding dementia [17–19], where it has been the pri-
mary outcome in clinical trials [20, 21].
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Objectives {7}
The primary objective of the trial is to evaluate the effect
of NIDUS-family and usual care on goal attainment as
measured by Goal Attainment Scaling (GAS) rated by
family carers, compared to usual care alone, at 12-
month follow-up.
The secondary objectives are to evaluate the effect of
NIDUS-family and usual care compared to usual care at
12 month follow-up on:
 Researcher rated Goal Attainment Scaling (GAS)
scores [21, 22]
 Functional independence (basic and instrumental
activities of daily living) as measured by the
Disability Assessment for Dementia Scale (DADS)
[23].
 Quality of life of the person living with dementia as
measured by the Dementia Quality of Life Scale
(DEMQOL) and/or the DEMQOL proxy completed
by the family carer [24];
 Neuropsychiatric symptoms as measured by the
Neuropsychiatric Inventory (NPI) [25];
 Family carer quality of life as measured by the
CarerQol [26];
 Apathy in the person living with dementia as
measured by the brief Dimensional Apathy Scale (b-
DAS) [27];
 Family carer anxiety and depression as measured by
the Hospital Anxiety and Depression Scale (HADS)
[28];
 Potentially abusive behaviours of family carers as
measured by the Modified Conflict Tactics Scale
[29];
 Service use and care costs assessed using the Client
Services Receipt Inventory (CSRI) [30];
 Duration of time living at home (time spent living at
home during the study, up to the point of, if they
occur, hospitalisation without return home, move to
a care home or death).
Trial design {8}
The trial is a two-armed, parallel group, single masked,
multi-site, superiority randomised controlled trial. Ran-
domisation is blocked and stratified by site using a 2:1
allocation ratio (two dyads are randomised to the inter-
vention group for every one dyad randomised to the
usual care group).
Methods: participants, interventions, and
outcomes
Study setting {9}
We are recruiting potential participants via clinicians
and research nurses working in NHS Trust memory
clinics/older adult mental health services and GP
practices based in London, Bradford, Leeds, Hull,
Oxfordshire, Buckinghamshire, Kent, Essex, and Surrey
and directly via the recruitment database Join Dementia
Research and Twitter. Subsequent to protocol
amendments made in response to COVID-19 and before
study commencement, informed consent, outcome as-
sessments, and intervention delivery are conducted via
telephone or video call, depending on individual partici-
pant preference; prior to COVID-19 restrictions, we ex-
pected that outcome assessments and intervention
sessions would be face to face, and if restrictions are
lifted and it is safe to do so during our recruitment
period (planned: April 2020 to February 2022), we will
also offer this option to participants. At time of writing
(October 2020), all trial processes have been conducted





People living with dementia/family carer dyads who
meet the following inclusion criteria will be recruited:
People living with dementia
 Documented diagnosis of dementia of any type and
severity
 Adults aged 18+ (no upper age limit)
 Living in their own homes (including sheltered
accommodation, where staff are not on site 24 h a
day): alone or with others
 Have a family carer/friend willing to participate in
the study who is in regular (at least weekly face-to-
face or telephone) contact with them;
Family carers/friends
 Family member or friend of the person living with
dementia
 Have at least weekly face-to-face or telephone con-
tact with the person living with dementia (not ne-
cessarily living with them)
 English speaking
People will be excluded from participation in the study
if they meet any of the following criteria:
People living with dementia
 Receiving palliative care support and considered to
be in the last 6 months of their life
 Currently enrolled in another intervention trial/
research study
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Family carers
 Lack capacity to consent
 Currently enrolled in another intervention trial/
research study
 Unable to identify three goals that support living
well/independence at home and within the
intervention remit at baseline
Who will take informed consent? {26a}
Trained researchers will assess capacity to consent. They
will obtain verbally-recorded or written informed con-
sent (by post after phone or video call discussion; or face
to face if COVID-19 restrictions allow) from each family
carer and person living with dementia prior to participa-
tion, following adequate explanation of the aims,
methods, anticipated benefits, and potential hazards and
burdens of the trial. Consent will be sought at least 24 h
after potential participants have been given the study
documentation. The researcher will explain that partici-
pants are under no obligation to enter the trial and that
they can withdraw at any time during it, without having
to give a reason. Family carers of people who lack cap-
acity to consent will be asked to complete a consultee
declaration form on behalf of their relative with
dementia.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
We will not collect biological specimens from
participants, so this section does not apply.
Interventions
Explanation for the choice of comparators {6b}
Participants randomised to the control group will
continue to receive usual care from NHS memory
services, GP practices, and any other health and social
care services during the trial period. The Quality and
Outcomes Framework (QOF) recommends the
development of dementia care plans that address physical
and mental health, communication arrangements with
secondary care, and identification of a carer in primary
care and a face-to-face review every year; in practice,
around half of people living with dementia in the UK have
a documented annual review [31].
Intervention description {11a}
The intervention is delivered over a 1 year period: 6–8
manualised sessions within the first 6 months, by video
call/telephone (with potential for face to face when
COVID-19 restrictions permit), followed by catch-up
calls every 1–2 months (at preference of participating
dyad) to review progress towards goals and troubleshoot
any difficulties for the remainder of the intervention
period. The manualised sessions are tailored to partici-
pant’s preferences and needs for staying independent at
home. In session one, the facilitator explores the partici-
pant’s identified goals and maps them to a menu of
training modules, based on their priorities and concerns
around maintaining independence at home. They also
explore their support networks and identify gaps, sign-
posting participants to existing resources and services.
The modules include information and strategies address-
ing the following areas:
 Accepting care, arranging, and planning for the
future
 Communicating with people living with dementia,
family, and professionals
 Managing behaviours and challenging behaviours
 Managing physical health conditions
 Exercise, activity, and mobility
 Managing low mood, anxiety, and apathy
 Carer wellbeing and support
 Safety, environment, telecare, strategies supporting
functioning at home
 Relaxation and stress management strategies
 Sleep, diet, and healthy routines
Each of these modules, if selected, is completed over
1–3 sessions; so, we anticipate most dyads will have the
opportunity to complete between 2 and 4 modules. At
the final appointment (the 6th, 7th or 8th session
depending on the needs and preference of the dyad), the
facilitator brings together old and new strategies that
have worked to help the participant formulate a final
action plan. They then conduct telephone calls every 1–
2 months to offer support and guidance on
implementing strategies and to troubleshoot any
problems. Sessions are delivered to family carers and
people living with dementia together or to the family
carer alone. This is agreed with each dyad (depending
on their goals and circumstances) so that the most
appropriate arrangement is made for each session for
each dyad.
The University College London (UCL) and University
of Bradford (UoB) employed facilitators have been
trained to deliver the NIDUS-family intervention to
people living with dementia at home and their family
carers. The intervention delivery training is provided by
members of the research team (including an old age
psychiatrist (CC), clinical psychologists (MP/PR) and the
trial manager (AB), and research network volunteers
from the Alzheimer’s Society (MO, DS). Initial training
took place over 9 days face to face between January and
March 2020. Taught content included clinical skills,
taught by a clinical psychologist, with most of the time
spent role-playing the sessions to practice delivery and
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troubleshoot scenarios that might arise. Role plays were
conducted within the UCL/UoB research teams, and fa-
cilitators also role played sessions with PPI representa-
tives with experience of caring, who then gave feedback
to the research team. Facilitators were signed off to de-
liver the first intervention session, subsequent interven-
tion sessions, and the final intervention session using
written sign off sheets completed by members of the re-
search team delivering the training. Facilitators attend
group supervision with a qualified clinical psychologist
every two weeks and can access individual support be-
tween formal supervision sessions if needed.
Criteria for discontinuing or modifying allocated
interventions {11b}
The intervention has been modified in response to
feasibility testing in a previous study [13], and therefore,
no further modifications to the intervention are planned.
The intervention is currently being delivered online/by
telephone as opposed to face-to-face in response to re-
strictions imposed by the COVID-19 pandemic to en-
sure participant and facilitator safety. The psychosocial
intervention has been assessed as low risk; therefore, we
have not set criteria for discontinuation; however, partic-
ipants may decide to discontinue the intervention ses-
sions or withdraw from the project at any point. If
participants decline the intervention at any point, they
will be asked if they would still wish to meet with the re-
searchers completing outcome assessments. Although it
will be stressed that participants can withdraw at any
time without giving a reason, any assessments that have
been collected to that point will be retained and contact
with participants will be maintained unless researchers
are told otherwise. All contacts with participants and
reasons for withdrawing from the intervention or study
will be documented on the study database.
Strategies to improve adherence to interventions {11c}
We are flexible in terms of delivery; this may enable a
subject to participate who would like to manage the
time commitment the intervention requires—for
example by sending material in advance and holding a
session of reduced length or combining two sessions
into one longer session where this is preferred by the
participant. Should a family carer withdraw from the
intervention, we will explore the possibility of involving
a second family carer, and, if they are eligible and
willing, we would consent them into the trial and invite
them to complete the primary outcome (GAS) and other
proxy complete follow-up questionnaires, but not the
follow-up questionnaires that relate to family carer well-
being. We will record and report where these adapta-
tions are made to support retention of participants in
the trial. Facilitators will receive guidance in the form of
intervention protocols and manuals. Throughout the
trial, facilitators will be supervised to ensure adherence
to protocol, with weekly update and monitoring meet-
ings. Audio recordings of 20% of intervention appoint-
ments will be used to assess fidelity to the intervention
manual, and details of how these will be rated are below.
Relevant concomitant care permitted or prohibited during
the trial {11d}
All relevant concomitant care and interventions are
permitted during the trial. Many of the people with
dementia taking part will be taking medications for
dementia symptoms and co-existing long-term condi-
tions as well as receiving health and/or social care ser-
vices. All prescribed medications and service use will be
recorded as part of the CSRI data collection. Participants
enrolled in other intervention research studies at the
time of recruitment will not be eligible to take part in
the study.
Provisions for post-trial care {30}
There are no arrangements to provide the intervention
to participants after the trial.
Outcomes {12}
All outcomes will be collected at baseline and 6 and 12
months.
Primary outcome
 The primary outcome is functioning of the person
with dementia assessed using family carer rated Goal
Attainment Scaling (GAS) at 12 months follow-up.
GAS is valid, reliable, and responsive to change in
function in people with dementia living at home up
to 12 months [21, 22]. Trained researchers will work
with family carers and people living with dementia
to set SMART (Specific, Measurable, Achievable,
Realistic and Time-bound) goals across domains in-
cluding: cognition, instrumental activities of daily
life/self-care, mood, behaviour, and mobility. Family
carers will evaluate ‘performance’ of the person liv-
ing with dementia (or carer wellbeing if the goal re-
lates to this) on a minimum of three and maximum
of five goals set at baseline, on a 5-point scale ran-
ging from ‘much worse’ to ‘much better’ than ex-
pected. As people will have different goals and
numbers of goals, a summary formula standardises
the degree of goal attainment [21], analysed as a
change score. We will calculate GAS for people with
dementia who have died, using procedures outlined
by Gordon et al. [32]. Where death was unexpected,
attainment in each domain will be rated as − 2.
Where death was expected (we exclude clients who
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are considered to be in their last 6 months of life,
but circumstances can change and we follow-up cli-
ents for 1 year), goals will be rated as achieved prior
to death.
Secondary outcomes
Researchers conducting follow-up assessments are asked
to provide their own rating on Goal Attainment Scaling
[22, 33].
Family carers are asked to proxy-complete:
 Disability Assessment for Dementia Scale (DADS), a
standard measure of functional independence (basic
and instrumental activities of daily living) [23].
 DEMQOL proxy, a widely used measure of quality
of life of people with dementia [24];
 Neuropsychiatric Inventory (NPI) [25];
 CarerQol [26];
 The brief Dimensional Apathy Scale (b-DAS) [27];
 Hospital Anxiety and Depression Scale (HADS) [28];
 Modified Conflict Tactics Scale to measure
potentially abusive behaviours [29]
 Client Services Receipt Inventory (CSRI) [30]
including home care, hospitalisations, respite, and
all-cause time to transition from home.
 People with dementia complete, if they are able to:
 Goal Attainment Scaling [21, 22], and
 DEMQoL to rate their quality of life [24]
Participant timeline {13}
Table 1 details the schedule and timing of assessments.
T9 and T14 represent the 6- and 12-month follow-up
points respectively. In the intervention group, the 6-8
main intervention sessions occur between 0 and 6
months (time point 0 and t9) and follow-up phone calls
to support implementation between T9 (6 months) and
T14 (12 months). Process evaluation interviews will be






















NIDUS-family Intervention sessions X X X X X X X X
NIDUS-family telephone follow-
ups
X X X X X
Assessments
Participant demographics X




DEMQOL/DEMQOL proxy X X X
Neuropsychiatric Inventory X X X
CarerQol X X X
Brief Dimensional Apathy Scale X X X
Hospital Anxiety and Depression
Scale (HADS)
X X X
Client Services Receipt Inventory
(CSRI)
X X X




Qualitative interviews (10% of
intervention sample)
X
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conducted after all the main outcomes have been com-
pleted (T15).
Sample size {14}
The sample size calculation is based on the primary
comparison of Goal Attainment Scaling change scores at
12 months between the intervention and usual care
groups. Assuming a moderate effect size of 0.5 [34], 198
intervention and 99 control subjects are required to
detect such a difference at a 5% significance level (2-
tailed) with 90% power. The calculation includes an
inflation for clustering due to therapist in the
intervention arm (intracluster correlation coefficient
(ICC) = 0.05 average cluster size = 20) and for up to
15% loss to follow-up [35]. The calculation of sample
size was carried out using STATA version 14.
Recruitment {15}
Researchers will recruit 297 family carer-people with de-
mentia dyads from memory services or older adult men-
tal health services in NHS Trusts and GP practices
supported by the Clinical Research Networks (CRNs):
North Thames, Thames Valley and South Midlands,
North West London, Kent, Surrey and Sussex, and York-
shire and Humber. We will aim to recruit 10–20 dyads
per trust or GP practice area.
Clinicians and research nurses are asked to contact
potential participants during the recruitment period.
Verbal permission will be sought from the person living
with dementia and the family carer (if present) from the
identifying clinician/research nurse, and they will
contact the researcher either by telephone or secure
email to inform them of any interested participants. The
researcher will then contact the person living with
dementia and their family carer at least 24 h after the
participant information sheet (PIS) has been given by
the clinician/research nurse in person, 48 h if it has been
sent via email, or at least 72 h if it has been sent by post.
A mail out will also be conducted to all potentially
eligible participants at participating GP practices. The
mail out will contain the relevant PIS and a letter asking
the family carer or person with dementia to indicate
their interest in participating in the study either by
calling a researcher or returning a reply slip. As
researchers receive responses, they will contact the
person with dementia and their family carer to answer
any questions they may have, check eligibility, determine
the context of the situation and relationship, and then, if
they would like to, make an appointment to elicit
informed consent and conduct the baseline assessment.
The study is also advertised through the social media
platform Twitter, the NIDUS study website, and the
research organisation Join Dementia Research.
Assignment of interventions: allocation
Sequence generation {16a}
Allocations will be obtained through a remote web
based system: www.sealedenvelope.com provided by
PRIMENT Clinical Trials Unit (CTU) and following
PRIMENT Standard Operating Procedures (SOP). The
randomisation list will be blocked and stratified by site
using a 2:1 allocation ratio (two dyads will be
randomised to the intervention group for every one dyad
randomised to the control). The 2:1 ratio was selected to
help enhance recruitment as more people will receive
the intervention than not, and because the intervention
is modular and highly individualised. By randomising
more people to receive it, we will obtain a greater
understanding of the intervention and the types of
modules selected.
Concealment mechanism {16b}
Randomisation status is concealed on the remote web
based system: www.sealedenvelope.com from the
researchers conducting outcome assessments. Only the
trial manager and the researcher assigned to deliver the
intervention are aware of the participant’s allocation
status.
Implementation {16c}
Researchers will enrol participants and collect baseline
data. They will enter the data onto the Sealed Envelope
database; then, as soon as data entry is complete, they
will instigate the randomisation procedure. Sealed
envelope provides the allocation on participant
registration.
Assignment of interventions: masking
Who will be blinded {17a}
The researchers collecting outcome data are blinded to
group allocations. Four-to-six researchers will work in
two small teams, and if a researcher delivers the inter-
vention from one team, a researcher from the other
team will conduct the outcome assessments for their
participants. Clinical supervision will be conducted with
the teams separately to avoid unblinding during discus-
sions. It will not be possible to blind trial participants or
researchers delivering the intervention to group alloca-
tion, nor will it be possible to blind the statisticians ana-
lysing the data due to the 2.1 participant allocation ratio,
though analyses will not commence until all data are
collected and the database has been locked.
Procedure for unblinding if needed {17b}
Researchers conducting the outcome assessments will
remain blinded to participant status throughout the
study unless this is accidently disclosed by a participant
during outcome assessments. The trial manager will be
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aware of treatment allocation status and will inform
clinical members of the study team of allocation status if
a serious adverse event occurs. No circumstances are
envisaged whereby the researchers assessing outcomes
will be purposefully unblinded.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data is collected at baseline and 6- and 12-month
follow-up for all participants (Table 1). Those in the
intervention group are asked to complete an additional
measure on acceptability of the intervention at the end
of the study. Approximately 10% of participants in the
intervention group will participate in an additional quali-
tative interview about their experiences of receiving the
intervention. All researchers are fully trained to use the
data collection tools. All outcome assessments will be
measured using validated questionnaires (please refer to
the ‘Objectives’ section of this protocol for a list of vali-
dated questionnaires that will be used in this trial).
Plans to promote participant retention and complete
follow-up {18b}
While face to face delivery is not possible due to
COVID-19 restrictions, we will offer a choice of video
call options or telephone contact where participants are
unable or do not wish to use video call. Participants will
be offered a £20 voucher to thank them for their time
after each follow-up appointment (baseline and 6 and
12months and qualitative interview).
Data management {19}
Data will be collected from participants manually on
trial specific paper case report forms (CRFs) which will
then be entered into a web-based clinical data manage-
ment system, Red Pill, provided by Sealed Envelope
through PRIMENT CTU. There is an agreement in place
between the sponsor (UCL) and Sealed Envelope to en-
sure compliance and agreement with clinical trial regula-
tions, GDPR, and data protection laws. Range checks for
data values have been built into the database to minim-
ise data entry errors.
Around 20% of GAS assessments and intervention
sessions (randomly selected) will be audio-recorded for
fidelity checking, and qualitative interviews will be re-
corded using a password protected recorder. Files will be
transferred between a professional transcription service
and UCL, UoB, and Anglia Ruskin University (ARU) via
a secure server hosted by the transcription service.
Audio files will be password protected and stored in sep-
arate folders to the transcripts on password-protected
computers at UCL, UoB, and ARU and will only be ac-
cessible to members of the research team authorised to
use them.
Confidentiality {27}
Personal data needed to re-contact participants for
follow-up assessments and intervention sessions will be
held securely on password protected excel spreadsheets
on password-protected computers at UCL, UoB, and
ARU (all co-applicants on the study). Data will be stored
electronically in folders only accessible to the research
team. Data collected at baseline and follow-up will be
collected on case report forms (CRFs) that will not bear
the participant’s name; only the participant’s trial identi-
fication number and date of birth will be used for identi-
fication, and this will be clearly explained to the
participant in the PIS; these will be held securely in
locked premises accessible only to the research team.
Consent forms will be held electronically on password-
protected computers at UCL and UoB. Only members of
the research team will have access to these forms.
Audio files from recorded intervention sessions and
qualitative interviews will be transcribed and all
identifiable information will be removed from the
transcripts including any reference to names or places.
Audio files will be deleted from the recording device
immediately after the safe upload has been confirmed.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
We will not be collecting any biological specimens for
this study; therefore, this section is not applicable.
Statistical methods
Following PRIMENT SOP, the detail of statistical
analyses will be described in a separate statistical
analysis plan that will be agreed before final trial data
are made available.
Statistical methods for primary and secondary outcomes
{20a}
Baseline demographic and questionnaire data will be
summarised by treatment group using means (with
standard deviations), medians (with interquartile ranges),
counts, and proportions, as appropriate, to gauge the
balance in characteristics between the randomised
groups.
Primary outcome analysis
Family carer-rated Goal Attainment Scaling (GAS) glo-
bal mean scores at 12 month follow-up will be sum-
marised for the NIDUS-family and usual care groups
using means with standard deviations. The outcome will
be compared between the groups using a three level
mixed effects model which allows for intervention arm
therapist clustering and also includes a random effect
for study site. The treatment effect estimate from this
Burton et al. Trials          (2021) 22:865 Page 9 of 14
model will be the adjusted difference in mean GAS score
which will be reported with a 95% confidence interval
and P value. Analyses will be carried out based on the
intention to treat principle, comparing the groups as
randomised regardless of adherence to the intervention.
Secondary outcome analysis
Analyses of the continuous secondary outcome scores
will take a similar approach to the analysis described for
the primary outcome; however, models for these
outcomes will additionally include adjustment for the
associated baseline measurement.
Economic evaluation
The incremental cost per quality-adjusted life year
(QALY) gained with the NIDUS-family intervention
compared to usual care will be calculated over the 12-
month duration of the trial. The primary cost analysis
will be from NHS and personal and social services per-
spective and include NIDUS-family intervention cost in
the treatment arm and resource use costs in both arms
[36]. The cost of the intervention will include the cost of
training, supervision, and staff time to deliver NIDUS-
family intervention costed at the relevant staff grade
[37]. We will collect information on impact on family
carers for a societal perspective analysis. Resource use
on health and social care will be collected using an
adapted version of the CSRI and will be costed using the
most recent nationally published sources [37].
QALYs will be calculated based on participant and
family carer responses to the DEMQOL/DEMQOL
proxy using the DEMQOL-U/DEMQOL-U-proxy classi-
fication system [38]. QALYs will be calculated as the
area under the curve adjusting for baseline differences.
Means and 95% confidence intervals for all key results
will be reported. These will be calculated using
bootstrapping, adjusting for baseline and including the
same covariates as specified in the statistical analysis
plan. In addition, missing data will be addressed as
specified in the statistical analysis plan.
Cost-effectiveness planes and cost-effectiveness ac-
ceptability curves for a range of values of willingness-to-
pay for a QALY gained will be reported using the boot-
strapped results.
Qualitative analysis of interviews
After completion of final follow-up, a 10% sub sample of
participants who received the NIDUS-family interven-
tion will be interviewed to explore their experiences of
receiving the intervention and to inform adaptations and
improvements to the intervention for wider roll out.
This should be sufficient to reach theoretical saturation.
People will be purposively recruited with varying socio-
demographic characteristics to comprise a maximum
variation sample, and we will invite for interview those
who did not complete the intervention as well as com-
pleters to gain differing opinions. NVivo software will be
used for qualitative data analysis, and a thematic analytic
approach to analysing transcripts will be taken [39]. Two
researchers will systematically code the transcripts into
meaningful fragments and label these initial codes. Dis-
crepancies will be discussed and resolved with the inves-
tigators overseeing the trial. The researchers will then
organise the data into preliminary themes. They will dis-
cuss the coding frames within the NIDUS team using
the constant comparison method to identify similarities
and differences in the data. Emerging analyses will also
be discussed with the NIDUS PPI group. The process
evaluation data collection will be led from the ARU site,
who are not involved in data collection for the main
trial, and they will also lead the analysis of the process
evaluation data, to reduce risk of bias.
Quantitative evaluation of intervention acceptability
After completion of final (12 month) study outcomes,
intervention participants will be asked to rate
acceptability of the intervention on a 5-point Likert scale
by responding to the statement ‘the intervention helped
the person I care for’ with 1 indicating strongly disagree
and 5 indicating strongly agree with space for free text
feedback on their experience of receiving the
intervention.
Fidelity analysis
To analyse fidelity of delivery of NIDUS-family, the
number of appointments delivered across all interven-
tion participants will be assessed. A random sample of
20% of appointments will be audio-recorded, tran-
scribed, and checklists applied independently by two re-
searchers. A mean fidelity score will be produced by
dividing the number of items on the checklist identified
as being delivered in the appointment, by the number of
items on the checklist that should have been delivered.
Thresholds used in other intervention fidelity work will
be adopted [40]: where 81–100% constitutes high fidel-
ity, 51–80% is moderate fidelity, and 50% or lower con-
stitutes low fidelity.
Interim analyses {21b}
As this is a trial of a psychosocial intervention and the
intervention is low risk, we do not plan interim analyses.
Should the independent combined Programme
Management Group/Data Monitoring and Ethics
Committee (PMG/DMEC) consider it necessary, they
will request this and liaise with the CTU and trial
sponsor.
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Methods for additional analyses (e.g. subgroup analyses)
{20b}
The following supportive analyses will be carried out for
the primary and secondary outcomes using the same
modelling approaches as described in the ‘Statistical
methods’ section of this protocol:
• Adjusted analyses allowing for other predefined
factors related to the outcome (whether the family carer
participating was living with the care recipient and
whether the care recipient had capacity to give informed
consent to participate (as an index of dementia
severity)).
• Estimation of the treatment effect adjusting for any
concerning imbalances in baseline characteristics.
Subgroup analyses will explore the primary outcome
in (1) those who receive a minimum ‘dose’ of the
intervention, relative to the control group and those
who do not, and (2) between participants receiving the
intervention predominantly by telephone, video call, and
(if applicable) face to face (3).
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
The number of subjects with missing data by reason will
be examined for each randomisation group (and for
each outcome). Characteristics of participants with and
without missing outcome data will be compared using
logistic regression models (with missing yes/no as the
outcome) and characteristics that predict missingness
identified. In a sensitivity analysis, the treatment effect
will then be re-estimated with additional adjustment for
baseline predictors of missingness. Further analyses
based on multiple imputation methods will be consid-
ered if appropriate. Analyses will be carried out based on
the intention to treat principle.
Plans to give access to the full protocol, participant level-
data, and statistical code {31c}
The trial protocol is available via the ISRCTN registry
(ISRCTN11425138). Participant-level data will be man-
aged by PRIMENT CTU and made available on request,
based on the SOP. The statistical code will be disclosed
by the senior statistician on receipt of a reasonable
request.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
The study will be overseen by clinical academics based
at UCL Division of Psychiatry, PRIMENT CTU, a
Programme Management Group (PMG), and
independent trial steering committee (TSC). The PMG
will include the chief investigator, co-investigators, the
trial manager, trial statisticians, health economists,
researchers, research network volunteers, and represen-
tatives from PRIMENT CTU. The PMG will be respon-
sible for overseeing the trial. The TSC will be chaired by
an independent clinical academic and will include an in-
dependent statistician and three research network volun-
teers, two PRIMENT CTU representatives alongside the
CI, trial manager, and lead statistician for the study.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The DMEC is combined with the PMG, as agreed with
PRIMENT CTU and the funder, because this is a low
risk intervention trial.
Adverse event reporting and harms {22}
Any serious adverse events (SAEs) which are classified
as related and unexpected will be reported to the chief
investigator (CI) of the study in the first instance and
the local principal investigator (PI)/participant’s GP/
clinician. The TSC and PRIMENT CTU will review
serious adverse events and events will be reported to the
research ethics committee (REC) that approved the trial.
All parties will be kept informed of serious adverse
events via the trial manager. All SAEs will be recorded
on the online database hosted by Sealed Envelope. The
CI/PI or designated researcher will complete the SAE
form and the form will be preferably emailed to
PRIMENT CTU within 24 h of becoming aware of the
event by the trial manager. The CI or PI will respond to
any SAE queries raised by the sponsor as soon as
possible.
Frequency and plans for auditing trial conduct {23}
The PMG will meet approximately twice a year. Its
remit is to review recruitment figures, serious adverse
events and substantial amendments to the protocol prior
to submission to the REC. The study team will also
consult the independent TSC twice a year to provide
overall supervision of the trial. The TSC will review the
recommendations of the PMG and, on consideration of
this information, recommend any appropriate
amendments/actions for the trial as necessary.
Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}
The trial manager will submit any protocol amendments
to the sponsor for approval prior to submission to the
REC. The trial manager will communicate amended and
approved documentation to all researchers and research
sites involved in the study and will update the trial
registry with any additional or revised study information.
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Dissemination plans {31a}
We will work with our PPI group in developing our
dissemination plans. Findings will be disseminated in a
peer reviewed journal, at an international conference,
and will be presented in appropriate local forums for
health and social care professionals. Participants who
have indicated they are interested in the results will be
sent a lay summary of the findings by post or email.
Discussion
To our knowledge, this is the first manualised
intervention tailored to personalised goals of people
living with dementia and their families, delivered by
facilitators without clinical training. GAS, our selected
primary outcome, can detect clinically meaningful
outcomes [16], through measuring the extent to which
individual patients or their families meet the goals that
they set. Our approach of using GAS as both an
outcome measure and to directly inform a non-
pharmacological intervention for people living with de-
mentia and their families, and to train non-clinical staff
to set goals, is novel.
GAS can serve as a co-intervention, where setting a
goal is key to achieving it [41]. For this reason, various
means of modifying the process have been developed, in-
cluding standardised, protocol-specific training [42] and
semi-standardised menus [43], which we will employ.
Limitations of GAS include the sometimes cumbersome
process of setting and adjudicating individual goals [44]
and a current lack of good quality validity studies [45].
While there will be heterogeneity in goals set, this is
remedied through its employment in a randomised con-
trolled trial, with masking of who has received the inter-
vention, and with patient assignments to treatment arms
occurring only after goals have been set [33].
There have been operational issues associated with the
shift to remote delivery. We worked collaboratively with
Rockwood’s team to ensure the goals we set using GAS
were SMART, including being achievable and relevant
to the uncertain COVID and post-COVID world. A par-
ticular concern was to avoid goals where achievement
would be dependent on lifting of lockdown restrictions.
Researchers received additional training in delivering re-
mote interventions and supporting participants to set up
video calls. We have considered carefully how to support
researchers delivering the intervention from their own
homes and to ensure the boundaries of sessions are
maintained in this new format; regular clinical supervi-
sion has been key to addressing this. Session content has
also been adapted, as discussed in the ‘Introduction’ sec-
tion. Remote delivery means that the format of our
intervention is further from that delivered in our feasi-
bility trial than originally intended. In the light of
COVID-19, there have been considerable recent efforts
to explore how remote and face-to-face psychological
intervention delivery may differ in their impacts; one re-
view reported minimal to no difference between tele-
phone and face-to-face therapy in terms of the nature of
the interaction between the therapist and client [46], but
more information will emerge as we assimilate know-
ledge from the sudden shift to remote delivery in spring
2020. The usual care received by all participants will also
have shifted to mainly remote delivery during lockdown,
and social care receipt will have reduced. While we
could not have envisaged the huge shifts to telecare the
pandemic has enforced, NIDUS-family was always
intended as a pragmatic intervention, comparing tai-
lored, structured additional support sessions to usual
care. The pragmatic and flexible nature of the interven-
tion has enabled us to continue evaluating it throughout
this period.
Trial status
Protocol version number 3: 6 April 2020. The first
participant dyad was recruited on 3 April 2020.
Recruitment will cease in February 2022.
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